Previous 10 | Next 10 |
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2019 financial results on Thursday, April 25, 2019. AtriCure will host a conference call ...
Intuitive Surgical (NASDAQ: ISRG ) initiated with Buy rating and $630 (9% upside) price target. Shares up a fraction premarket. More news on: Intuitive Surgical, Inc., AtriCure, Inc., Quest Diagnostics Incorporated, Healthcare stocks news, Stocks on the move, , Read more ...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the Needham & Company’s 18 th Annual Healthcare Conference in New York on Wednesday, April 10...
AtriCure Inc. (ATRC) Q4 2018 Earnings Conference Call February 28, 2019 4:30 PM ET Company Participants Lynn Lewis – Investor Relations Mike Carrel – President and Chief Executive Officer Andy Wade – Senior Vice President and Chief Financial Officer Confer...
AtriCure (NASDAQ: ATRC ) Q4 results ($M): Revenues: 52.9 (+14.8%); U.S.: 43.1 (+19.1%). More news on: AtriCure, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...
AtriCure (NASDAQ: ATRC ): Q4 Non-GAAP EPS of -$0.21 misses by $0.04 ; GAAP EPS of -$0.09 beats by $0.08 . More news on: AtriCure, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
2018 Worldwide revenue of $201.6 million – an increase of 15.4% year over year 2018 U.S. revenue of $162.1 million – an increase of 17.2% year over year 2018 International revenue of $39.5 million – an increase of 8.7% year over year Atri...
ACHC , ADSK , AGO , AIMT , ALRM , ALTR , AMBC , AMC , APPF , AQN , ATRC , BIO , BLDR , CARG , CISN , CSLT , DCO , DDD , DELL , EDIT , EIX , EQH , FTCH , GCAP , GPS , GSBD , HABT , ICUI , JAG , JWN , KTOS , KWR , LYV , MAIN , MAR , MAXR , MTZ , NKTR , N...
Endorsement complements the company’s ongoing commitment to physician education AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced that The Society of Thoracic Surgeons (S...
cryoSPHERE probe launched in United States, designed exclusively for post-operative pain block AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced that it has launched the cryoICE ...
News, Short Squeeze, Breakout and More Instantly...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Canaccord Genuity 44th...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has received regulatory approval from the National Medical Products A...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2024 financial results on Tuesday, Ju...